OSRX, Inc., Missoula, MT
Is OSRX, Inc. an FDA-registered 503B outsourcing facility?
Yes. FDA’s registered outsourcing facility list, updated Nov 6, 2026, names OSRX, Inc. in Missoula, MT, first registered Oct 28, 2023 and most recently registered Dec 29, 2025. FDA lists its last inspection as Nov 14, 2025, with a Form FDA 483 issued; FDA lists the action on that inspection as “Response Letter Issued 4/15/2026”.
FDA registers outsourcing facilities under section 503B; state boards of pharmacy issue pharmacy licenses separately. FDA’s list does not say which drugs a facility makes.
- Location on FDA’s list
- Missoula, MT
- Initial registration
- Oct 28, 2023
- Most recent registration
- Dec 29, 2025
- Last inspection
- Nov 14, 2025
- Form 483 issued at last inspection
- Yes
- Recall after last inspection
- No
- Action on last inspection
- Response Letter Issued 4/15/2026
- Intends to compound sterile drugs from bulk substances
- Yes
FDA inspections and actions on record
FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this facility as OSRX, Inc., Missoula, MT, a 503B facility, with 3 listed actions, including 2 Form 483s and 1 warning letter (2024 to 2025).
| Document | |||
|---|---|---|---|
| Nov 14, 2025 | Form 483 | 483 Issued 11/14/2025 | fda.gov |
| Apr 23, 2025 | Warning letter | Warning Letter Issued 04/23/2025 | fda.gov |
| Oct 25, 2024 | Form 483 | 483 Issued 10/25/2024 | FDA copy (archived) |
A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own.
Matched to the 503B list by city, state and the exact legal name with the same legal ending. Check the heading above against the facility you are looking for.
FDA inspection classifications and published Form 483s
The FDA Data Dashboard, read Nov 15, 2026, lists OSRX Inc., Missoula, MT (FEI number 3014549846), matched to this page by exact name, city and state. It lists 3 inspections: 1 OAI, 2 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.
| Inspection ended | Classification | Project area and product type | FEI | Inspection ID |
|---|---|---|---|---|
| Oct 25, 2024 | Official Action Indicated (OAI) | Drug Quality Assurance (Drugs) | 3014549846 | 1246254 |
| Sep 23, 2021 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3014549846 | 1154392 |
| Apr 25, 2019 | Voluntary Action Indicated (VAI) | Drug Quality Assurance (Drugs) | 3014549846 | 1087576 |
Form 483s FDA has published for this site
- Nov 14, 2025: Form 483 to OSRX Inc., published Jan 16, 2026. fda.gov
- Oct 25, 2024: Form 483 to OSRX Inc., published Nov 21, 2024. fda.gov
- Sep 23, 2021: Form 483 to OSRX Inc., published Feb 24, 2022. fda.gov
- Apr 25, 2019: Form 483 to OSRX Inc., published Jul 15, 2019. fda.gov
FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.
Form 483 observations
A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.
FDA’s published Form 483s for this site have 12 numbered observations in all, across 4 inspections ending Apr 25, 2019 to Nov 14, 2025. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.
Inspection Nov 3, 2025 to Nov 14, 2025: 4 observations
- Firm on the cover
- OSRX Inc., 1120 Kensington Ave, Missoula, MT 59801-5619
- FEI number
- 3014549846
- Establishment type on the cover
- Outsourcing Facility
- FDA district office on the cover
- 22215 26th Ave SE Suite 210 Bothell, WA 98021
- Matched to this page by
- FEI number on the cover; linked from actions page, 503B list, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not followed.
Specifically,
B. Your firm's personal media fills (to qualify personnel) and aseptic process simulations (to qualify the process) do not closely simulate routine production operations. During routine production, personnel can:
• Fill or add tips to <Redacted B4> droptainers of Atropine Sulfate Monohydrate 0.025% Ophthalmic Solution 3.5 ml, Lot 206446, BUD: 29JUN2026 or
4 • Fill or add septums (stoppers) to (<Redacted B4>) vials of Dexamethasone Phosphate 0.1% + Moxifloxacin Hydrochloride 0.5% Ophthalmic Injection 1 ml, Lot 206594, BUD: 14APR2026.
However, during personnel media fills and aseptic process simulations, the operator will sometimes fillless. For example:
As part of SOP-CC-0025 Personal Media Qualification, Version 3, Effective Date: <Redacted B4> I21FEB2025, personnel perform passing personal media fills on . Each personal media fill requires them to do line set up and fill no less than an <Redacted B4> droptainers. They subsequently add the tips/caps within the same media fill. There are no personal media fills performed with vials. ...
Observation 2
Written records of investigations into unexplained discrepancies do not always include the conclusions and follow-up.
Specifically,
• On 24FEB2025, your pharmacist received a report <Redacted B4> from a patient regarding drug product Prednisolone Phosphate 1 % + Moxifloxacin 0.5% + Bromfenac 0.075% Ophthalmic Solution 8ml, Lot 105095, BUD: 15JUN2025. The patient stated that the product caused a burning sensation in the eye for at least five minutes each time they used it (3 times total). This was not forwarded to quality assurance based on the pharmacists's discretion. No investigation was documented.
b. On 09JUL2025, your pharmacist received a report <Redacted B4> from a patient regarding drug product Prednisolone Phosphate 1 % + Bromfenac 0.075% Ophthalmic Solution 5ml, Lot 205126, BUD: 10JAN2026. The patient stated that she found a very tiny floating thing ( orangish/yellowish) after she used the eye drops. The medication incident form indicated that this report was forwarded to quality assurance, but quality assurance did not receive it.
C. Investigation of complaints is not adequate. The firm received the following complaints:
Quality Event# Complaint Date Reported ...
Observation 3
The reproducibility of test methods have not been established.
Specifically,
Your firm uses <Redacted B4> a <Redacted B4> test method, for sterility testing release of finished drugs. However, there is no established procedure to identify organisms to the species in the event of a sterility failure.
Observation 4
Appropriate controls are not exercised over computers or related systems to assure that changes in master production and control records or other records are instituted only by authorized personnel.
Specifically,
Audit trail review of your instruments HPLC <Redacted B4> and HPLC <Redacted B4> is not performed for each analytical record prior to release of each drug product. HPLC <Redacted B4> is used to test assay for the analytes Pred-Moxi-Brom (s) and Atropine(s). HPLC <Redacted B4> is used to test <Redacted B4> and for research and development. For example, Atropine Sulfate Monohydrate 0.025% Ophthalmic Solution 3.5 ml, Lot 206446, BUD: 29JUN2026 was tested on HPLC <Redacted B4> for Atropine(s) and released without audit trail review.
analytes Pred-Moxi- Brom (s) and Atropine(s). HPLCl~l is used to test I 41 <bH and for research and development. For example, Atropine Sulfate Monohydi·ate 0.025% Ophthalmic Solution 3.5 ml, Lot 206446, BUD: 29JUN2026 was tested on HPLCJ~: for Atropine(s) and released without audit trail review.
record prior to release of each diug product. HPLC~i:: is used to test assay for the I
Inspection Oct 16, 2024 to Oct 25, 2024: 6 observations
- Firm on the cover
- OSRX Inc., 1120 Kensington Ave, M issoula, M T 5 9801-5 619 This doounent lists observations made by the FDA representative(s) during 1he inspection of your facility. They are inspectional observations, and do not represent a final Agency determination regarding your compliance. If you have an objection regarding a n observation, or have implemented, or plan to implement, corrective action in response to an observation, you may discuss the objection or action with the FDA representative(s) during the inspection or submit this information to FDA at the address above. If you have an y questions, please contact FDA at the phone number and address above.
- FEI number
- 3014549846
- Establishment type on the cover
- Outsourcing F acility
- FDA district office on the cover
- 22215 26th A ve S E S uite 21 0 Bo thell, WA 980 21
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.
Observation 1
Procedures designed to prevent microbiological contamination of diug products purporting to be sterile are not established and followed.
Specifically,
A. Your firm's personal media fill is deficient in that aseptic operators only aseptically fill <Re
dacted B4> containers units , <Redacted B4>, to fully qualify their sterile operators, under p rocedure, SOP-CC-0003, Personnel Media Fill Qualification. For example, to success fully qual ify operator, <Redacted B6> <Redacted B7> (C) to produce sterile drug
produc t in your cleanroom only <Redacte d B4> units were filled aseptically, taking a total of <Redacted B4> to manufacture. This is no t an adequate assessment of an operators aseptic technique when man ufacturing a maximum b atch size of <Redacted B4> units that take <Redacted B4> to complete.
B. Your firm failed to incubate all integral units of the media fill performed under protocol VALRPT-001. In Cleamoom Suite 100, the following units were filled in ISO 5 BSC and then removed for <Redacted B4> testing and production loss reasons. All units removed were not incubated with documented justification:
Droptainers:
Lots Filled Units Total Removed In cubated Units
Vials: ...
Observation 2
There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
Specifically,
A) Your firm failed to thoroughly investigation quality events that had environmental monitoring
recoveries that exceeded specification limits without adequate corrective actions, scientific justification, and impact assessment documented. For example,
i. QA-2024-0048 was initiated due to 1 cfu recove1y of Staphylococcus epidermidis on an ISO 5 active viable air sample plate that was performed during the production of Brimonidine tartrate/ dorzolamide 1% 2%, Lot<Redacted B4>, BUD: 23July2024. The batc h was released withou t the proper batch impact assess ment, corre ctive actions , and scien tific rati onale ap pli ed t o the event pri or to rele asin g and distrib utin g the drug pr odu ct to market.
ii. QA-2024-0071 was i nitiated due several e nvironmental recoveries in Cleanroom Suite 1 ...
Observation 3
Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.
Specifically,
A) There are no ISO 5 viable surface samples taken during the earlier lots being manufactured in
clean room# <Redacted B4>, (ISO7) and clean room#<Redacted B4> (ISO7) on each day of aseptic p roduction. For example, Atropine 0.01%, Sulfate Monohydrate, Lot <Redacted B4>, BUD 14Apr25, and Prednisolone Phosphate 1 % / Moxifloxacin 0.5% / Bromfenac 0.075%, Lot<Redacted B4>, BUD: 15Apr25, both were manufactured on <Redacted B4> and did not have an associated surface sample of the ISO 5 Biosafety Cabinet performed at the end of each batch operation.
B) Your firm's procedure, SOP-CC-0026, Routine Environmental Monitoring Cleanroom 100, lists the action level for viable surface sample at <Re dacted B4> colonies performing units per samplin g device, which is not appropriate for an ISO 5 environment. ...
Observation 4
Each batch of drug product purporting to be sterile and pyrogen-free is not laboratory tested to determine conformance to such requirements.
Specifically, your firm performed an early release of drug product, Brimonidine Tartrate 0.1 %, Dorzolamide 2%, 2ml Ophthalmic Solution, Lot<Redacte d B4>, BUD:26May2024, without the sterility t esting being completed by your third pa1ty laborat ory as documented in QE-2024-0032.
Observation 5
The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.
Specifically, your firm's procedure SOP-INSP-0001, entitled, Visual Inspection of Sterile Compounde d Topica l Ophthalmi c Preparations , fail s t o implemen t adequat e specification s t o preven t significan t product quality issues from occurring, as follows:
A. There is no sound visual inspection program that contains a qualified visual inspection sample defect kit used to train visual inspectors to inspect topical ophthalmic solutions manufactured in opaque droptaine rs.
B. You does not examine 100% of units produced for topical ophthalmic drug products. Instead,
you only perfo1m an examination of <Redacte d B4> opaque topical droptainers as a form of Accept able Quality Limit (AQL) inspection without scientific rationale. Your firm only performs an 100% inspection of the rejected AQL inspection for that failed defect catego1y with a <Redac ted B4> AQL using the same accept/ reject limits.
Observation 6
The container of your outsourcing facility's drug products does not include information required b y section 503B(a)(10)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act).
Specifically, your containers do not include a label that includes the following information:
www.fda.gov/medwatch and 1-800-FDA- 1088 Information to facilitate adverse event reporting: www.fda.gov/medwatch and 1-800-FDA-1088; and B. Directions for use, including, as appropriate, dosage and administration.
A. Information to facilitate adverse event reporting:
www.fda.gov/medwatch and 1-800-FDA-1088; and
Examples of your container labels that do not contain this information:
i. Prednisolone Phosphate 1% Moxifloxacin 0.5% Bromfenac 0.075% 8mL Sterile Ophthalmic Solution ii. Atropine Sulfate 0.05% 3.5mL Sterile Ophthalmic Solution iii. Timolol 0.5% Brimonidine Tartrate 0.1 % Dorzolamide 2% 5mL Sterile Ophthalmic Solution iv. Moxifloxacin 0.5% Bromfenac 0.075% 5mL Sterile Ophthalmic Solution v. Prednisolone Phosphate I% Moxifloxacin 0.5% 5mL Sterile Ophthalmic Solution
vi. Prednisolone Phosphate 1% Moxifloxacin 0.5% Bromfenac 0.075% 8mL Sterile Ophthalmic Solution
xvii. ...
Inspection Sep 15, 2021 to Sep 26, 2021: 1 observation
- Firm on the cover
- OSRX, Inc. SMK 9/23/21, 1120 Kensington Ave., Unit E, Missoula, MT 59801
- FEI number
- 3014549846
- Establishment type on the cover
- Producer of Sterile Drug Products
- FDA district office on the cover
- hell, WA 98021 (42
- Matched to this page by
- FEI number on the cover; linked from actions page, Data Dashboard
- FDA document
- Read the full 483 (PDF on fda.gov)
This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.
Observation 1
Your firm's current laminar airfl ow studies (smoke studies) of the ISO 5 <Red acte d B4> Laminar Airflow Workstati on were not performed under conditions showing aseptic operations that are representative of your curren t compounding practices nor did they emulate all critical unit operations and interventions used during c ompounding of your sterile drug p roducts. Sp ecifically,
Smoke studies conducted by your firm, in May of 2021 were not conducted under dynamic conditions that fully simulate the normal operating conditions of the sterile drug production.
1) You did not simulate the entire filling process, including the priming of the pump used to fill the vials with the compounded drug product.
2) You also did not simulate the, practice of two operators working together in your ISO 5 L aminar Air Flow Hood
d uring fi ll ing, c ap pi ng and sea li ng operations.
Inspection Aug 28, 2018 to Apr 25, 2019: 1 observation
- Firm on the cover
- Pinnacle Compounding, 1120 Kensington Ave Unit E, Missoula, MT 59801-5619
- FEI number
- 3014549846
- Establishment type on the cover
- Compounding Pharmacy
- FDA district office on the cover
- 22215 26th Ave SE Suite 210 Bothell, WA 98021
- Matched to this page by
- FEI number on the cover; linked from Data Dashboard, actions page
- FDA document
- Read the full 483 (PDF on fda.gov)
Observation 1
<Redacted B4> intended to render final product sterile was not adequate to accomplish sterilization.
Specitically,
a. Your firm failed to conduct <Redacted B4> testing only <Redacted B4> used to sterilize Atropine Sulfate 0.01% Sterile Ophthalmic Solution, lot 021219OS1010, manufactured on 02/12/19, with a beyond-use date (BUD) of 180 days.
b. Your firm released products purported to be sterile despite the failure of the <Redacted B4> used in their production to meet the manufacturer's <Redacted B4> test specifications. For example:
Prednisolone/Ketorolac 1 %/0.5% Ophthalmic Solution, lot 021319OS1001, manufactured on 02/13/19, with a BUD of 180 days, was released with a <Redacted B4> testing result of <Redacted B4> which is below the manufacturer's specification of <Redacted B4>
Timolol/Brimonidine/Dozolamide 0.5%/0.2%/2% Ophthalmic Solution, lot 020720190S I006, manufactured on 02/07/19, with a BUD of 180 days, was released with a <Redacted B4> testing result of <Redacted B4> which is below the manufacturer's specification of <Redacted B4>
GLP-1 records in this index
No FDA warning letter or recall report naming a GLP-1 drug in this index, as of Nov 15, 2026, is addressed to this facility’s exact legal name (OSRX, Inc.). That is not a finding beyond this index’s search.
The OSRX, Inc. pharmacy page answers whether it has had a state board action or FDA letter, from the same FDA lists.
This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.
Sources
- FDA Registered Outsourcing Facilities (503B)
- FDA: Compounding: Inspections, Recalls, and other Actions
- FDA Data Dashboard: inspection classifications and published Form 483s
- FDA: FDA Form 483 Frequently Asked Questions
Records last pulled Nov 15, 2026. Every entry links to the original public record.